HK inno.N gains approval for domestic Phase 3 clinical trial of GLP-1 series obesity 바카라사이트 목록 candidate

[by Kang, In Hyo] HK inno.N has initiated full-scale Phase 3 clinical trials for its obesity treatment candidate. The company announced on May 8 that it received approval from the Ministry of Food and Drug Safety on May 7 for the domestic Phase 3 investigational new drug (IND) clinical trial for ‘IN-B00009 (ecnoglutide)’, a glucagon-like peptide 1 (GLP-1) receptor agonist (RA) for obesity treatment.

The Phase 3 clinical trial will involve obese or overweight adult patients without diabetes. Participants will receive either IN-B00009 or a placebo as a once-weekly subcutaneous (SC) injection to assess the 바카라사이트 목록’s efficacy and safety. The study is designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, with an expected completion date of May 2028. HK inno.N set the primary endpoints to include the ‘percentage change in body weight change at 40 weeks compared to baseline’ and ‘the proportion of participants achieving a weight loss of 5% or more.’

IN-B00009 is a GLP-1 RA that demonstrated safety and a statistically significant weight loss effect in a phase 2 clinical trial involving obese patients in Australia and New Zealand, with results showing superior efficacy compared to liraglutide after 26 weeks of 바카라사이트 목록. Additionally, in a phase 3 clinical trial conducted on local obese patients in China, the drug confirmed a substantial weight loss effect compared to placebo.

According to the ‘2024 Obesity Fact Sheet’ published by the Korean Society for the Study of Obesity, the prevalence of obesity among adults in Korea reached 38.4% over the past 10 years up to 2022, showing a continuous upward trend across both men and women. With the global obese population rising, the demand for effective obesity 바카라사이트 목록s is also increasing. The global obesity 바카라사이트 목록 market is projected to expand at an average annual growth rate of 14.4%, from USD 19.037 billion (approximately KRW 26.5813 trillion) in 2023 to USD 37.3671 billion in 2028.

“We will dedicate all our efforts to ensuring that IN-B00009 becomes a meaningful contribution to the 바카라사이트 목록 of obesity, a global health challenge,” an HK inno.N official said.

Conversely, IN-B00009 is a compound that HK inno.N licensed from the Chinese biotechnology company SCIWIND BIOSCIENCES CO., LTD. in 2024. The company has secured exclusive rights for development and commercialization in Korea and is pursuing its use as both an obesity 바카라사이트 목록 and a potential diabetes 바카라사이트 목록.